| Chronic Lymphocytic Leukemia |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.73 |
| Biologic Therapy |
0 |
0.62 |
| Lymphoma |
0 |
0.53 |
| CAR-T |
0 |
0.5 |
| B-Cell Lymphoma |
0 |
0.99 |
| Calcaneal |
0 |
0.43 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.32 |
| HIV Infection |
0 |
0.31 |
| Tyrosine Kinase Inhibitor |
0 |
0.97 |
| Genomic Medicine |
0 |
0.3 |
| Prolymphocytic Leukemias |
0 |
0.23 |
| Hodgkin Lymphoma |
0 |
0.22 |
| Mantle Cell Lymphoma |
0 |
0.98 |
| Biomedical Technology |
0 |
0.21 |
| Leukemia |
0 |
0.21 |
| Natural Killer (NK) Cells |
0 |
0.21 |
| T-Lymphocyte |
0 |
0.21 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.16 |
| Cell Transplantation |
0 |
0.15 |
| Stem Cell Research and Therapy |
0 |
0.15 |
| Antigens |
0 |
0.11 |
| Blood |
0 |
0.11 |
| Board Certification |
0 |
0.11 |
| Brachial |
0 |
0.11 |
| Clinical Research |
0 |
0.11 |
| Gene Regulation |
0 |
0.11 |
| Genetics |
0 |
0.11 |
| Hemoglobin |
0 |
0.11 |
| Immunotherapy |
0 |
0.11 |
| Monoclonal Antibody |
0 |
0.11 |
| Receptors |
0 |
0.11 |
| Transplantation |
0 |
0.11 |
| Tyrosine Kinase |
0 |
0.11 |
| Complementary and Alternative Medicine |
0 |
0.05 |